With disgorgement hopes dead, US FTC drops remaining claim in pay-for-delay suit against AbbVie
With its hopes of seeking disgorgement from the pharmaceutical giant dead, the US Federal Trade Commission has dropped the last claim in its pay-for-delay suit accusing Abbvie of insulating testosterone replacement...To view the full article, register now.
Already a subscriber? Click here to view full article